As a Partner of Pioneering Science, a virologist from Stanford University spoke to the newspaper about the challenges of developing medications to contain epidemics

During and after the Covid-19 pandemic, vaccines returned to the agenda. For months, the world followed the race to develop a vaccine that would help control the health emergency and celebrated (deniers aside) the distribution of doses.

However, vaccines are not the only strategy to contain epidemics: antivirals should be part of the solution. This is what Jeffrey Glenn, a virologist at Stanford University who visited Pioneering Science in March along with Victor Geddes, a fellow of the initiative, works on.

Before the pandemic, Glenn focused his research on developing medication to target the hepatitis C virus. With the arrival of Covid-19, his work shifted to the coronavirus. Now, this learning can be helpful in treating dengue.

During his visit to Brazil, the scientist granted an interview to O Globo, talking about the complementary action of vaccines and antivirals, the process of developing molecules to create medications, and the partnership with Pioneering Science, among other topics. Read the full interview (in Portuguese).